Inhibition of TrkB-associated signaling with ANA-12, which is a selective, small-molecule non-competitive TrkB antagonist that can cross the blood–brain barrier [290], has been found to limit the formation of astrocytomas [291] and the survival of GBM cancer cells [147]. Here, NTRK2 is linked to astrocytoma (excluding glioblastoma).